Monica Mazzarino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8156315/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In vitro metabolic profile of mexedrone, a mephedrone analog, studied by high―and lowâ€resolution mass spectrometry. Drug Testing and Analysis, 2022, 14, 269-276.	1.6	5
2	Urinary excretion and effects on visual placing response in mice of gamma-valero-lactone, an alternative to gammaâ€'hydroxy-butyrate for drug-facilitated sexual assault. Emerging Trends in Drugs, Addictions, and Health, 2022, 2, 100028.	0.5	3
3	Urinary excretion profile of methiopropamine in mice following intraperitoneal administration: A liquid chromatography–tandem mass spectrometry investigation. Drug Testing and Analysis, 2021, 13, 91-100.	1.6	10
4	Influence of Saw palmetto and Pygeum africana extracts on the urinary concentrations of endogenous anabolic steroids: Relevance to doping analysis. Phytomedicine Plus, 2021, 1, 100005.	0.9	2
5	Metabolic profile of the synthetic drug 4,4′-dimethylaminorex in urine by LC–MS-based techniques: selection of the most suitable markers of its intake. Forensic Toxicology, 2021, 39, 89-100.	1.4	7
6	Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques. Journal of Pharmaceutical and Biomedical Analysis, 2021, 195, 113849.	1.4	15
7	Urinary Elimination of Ecdysterone and Its Metabolites Following a Single-Dose Administration in Humans. Metabolites, 2021, 11, 366.	1.3	8
8	Effects of the administration of miconazole by different routes on the biomarkers of the "steroidal module―of the Athlete Biological Passport. Drug Testing and Analysis, 2021, 13, 1712-1726.	1.6	6
9	Worsening of the Toxic Effects of (±)Cis-4,4′-DMAR Following Its Co-Administration with (±)Trans-4,4′-DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. International Journal of Molecular Sciences, 2021, 22, 8771.	1.8	3
10	Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122989.	1.2	2
11	UPLC–MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine. Journal of Analytical Toxicology, 2021, 45, 184-194.	1.7	14
12	How reliable is dietary supplement labelling?—Experiences from the analysis of ecdysterone supplements. Journal of Pharmaceutical and Biomedical Analysis, 2020, 177, 112877.	1.4	12
13	Targeting the administration of ecdysterone in doping control samples. Forensic Toxicology, 2020, 38, 172-184.	1.4	31
14	Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of phthalates and bisphenol a in serum, urine and follicular fluid. Clinical Mass Spectrometry, 2020, 18, 54-65.	1.9	12
15	Carbon isotopic characterization of prednisolone and prednisone pharmaceutical formulations: Implications in antidoping analysis. Drug Testing and Analysis, 2020, 12, 1587-1598.	1.6	6
16	Detection and quantitation of ecdysterone in human serum by liquid chromatography coupled to tandem mass spectrometry. Steroids, 2020, 157, 108603.	0.8	7
17	Prescription Drug Misuse in "Clubbers―and Disco Goers in Ibiza. Frontiers in Psychiatry, 2020, 11, 592594.	1.3	5
18	Urinary excretion profile of prednisone and prednisolone after different administration routes. Drug Testing and Analysis, 2019, 11, 1601-1614.	1.6	14

MONICA MAZZARINO

#	Article	IF	CITATIONS
19	Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Archives of Toxicology, 2019, 93, 1807-1816.	1.9	75
20	Detection of recombinant insulins in human urine by liquid chromatography–electrospray ionization tandem mass spectrometry after immunoaffinity purification based on monolithic microcolumns. Analytical and Bioanalytical Chemistry, 2019, 411, 8153-8162.	1.9	9
21	Detection of 5αâ€reductase inhibitors by UPLC–MS/MS: Application to the definition of the excretion profile of dutasteride in urine. Drug Testing and Analysis, 2019, 11, 1737-1746.	1.6	6
22	Effect of nonâ€prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes. Drug Testing and Analysis, 2018, 10, 984-994.	1.6	3
23	A further insight into the metabolic profile of the nuclear receptor Revâ€erb agonist, SR9009. Drug Testing and Analysis, 2018, 10, 1670-1681.	1.6	15
24	Drug–drug interaction and doping: Effect of nonâ€prohibited drugs on the urinary excretion profile of methandienone. Drug Testing and Analysis, 2018, 10, 1554-1565.	1.6	6
25	The effect of zolpidem on cognitive function and postural control at high altitude. Sleep, 2018, 41, .	0.6	2
26	Liposomes as potential masking agents in sport doping. Part 2: Detection of liposomeâ€entrapped haemoglobin by flow cytofluorimetry. Drug Testing and Analysis, 2017, 9, 208-215.	1.6	4
27	Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normalâ€phase liquid chromatographyâ€ŧandem mass spectrometry. Drug Testing and Analysis, 2017, 9, 75-86.	1.6	4
28	Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography–mass spectrometry profiling: Relevance to doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 555-568.	1.4	16
29	Doping control container for urine stabilization: a pilot study. Drug Testing and Analysis, 2017, 9, 699-712.	1.6	7
30	<i>In vitro</i> evaluation of the effects of antiâ€fungals, benzodiazepines and nonâ€steroidal antiâ€inflammatory drugs on the glucuronidation of 19â€norandrosterone: implications on doping control analysis. Drug Testing and Analysis, 2016, 8, 930-939.	1.6	11
31	Drug-drug interactions and masking effects in sport doping: influence of miconazole administration on the urinary concentrations of endogenous anabolic steroids. Forensic Toxicology, 2016, 34, 386-397.	1.4	13
32	Multianalyte LC–MS-based methods in doping control: what are the implications for doping athletes?. Bioanalysis, 2016, 8, 1129-1132.	0.6	8
33	A multi-targeted liquid chromatography–mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117, 47-60.	1.4	22
34	Drug Use on Mont Blanc: A Study Using Automated Urine Collection. PLoS ONE, 2016, 11, e0156786.	1.1	16
35	Development and validation of a liquid chromatography–mass spectrometry procedure after solid-phase extraction for detection of 19 doping peptides in human urine. Forensic Toxicology, 2015, 33, 321-337.	1.4	31
36	Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies. Toxicology in Vitro, 2015, 30, 331-340.	1.1	8

#	Article	IF	CITATIONS
37	Narrowing the gap between the number of athletes who dope and the number of athletes who are caught: scientific advances that increase the efficacy of antidoping tests. British Journal of Sports Medicine, 2014, 48, 833-836.	3.1	21
38	Acute effects of physical exercise and phosphodiesterase's type 5 inhibition on serum 11β-hydroxysteroid dehydrogenases related glucocorticoids metabolites: a pilot study. Endocrine, 2014, 47, 952-958.	1.1	10
39	Drugâ€drug interaction and doping, part 2: An <i>in vitro</i> study on the effect of nonâ€prohibited drugs on the phase I metabolic profile of stanozolol. Drug Testing and Analysis, 2014, 6, 969-977.	1.6	23
40	Drugâ€drug interaction and doping, part 1: An <i>in vitro</i> study on the effect of nonâ€prohibited drugs on the phase I metabolic profile of toremifene. Drug Testing and Analysis, 2014, 6, 482-491.	1.6	9
41	A liquid chromatography–mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. Analytica Chimica Acta, 2014, 837, 70-82.	2.6	36
42	A simplified procedure for the analysis of formoterol in human urine by liquid chromatography–electrospray tandem mass spectrometry: Application to the characterization of the metabolic profile and stability of formoterol in urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 931, 75-83.	1.2	15
43	Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. Analytical and Bioanalytical Chemistry, 2013, 405, 5467-5487.	1.9	31
44	Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 248-254.	1.2	14
45	Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: Endogenous steroids urinary profile after multiple oral doses. Steroids, 2011, 76, 1400-1406.	0.8	28
46	Screening and confirmation analysis of stimulants, narcotics and beta-adrenergic agents in human urine by hydrophilic interaction liquid chromatography coupled to mass spectrometry. Journal of Chromatography A, 2011, 1218, 8156-8167.	1.8	42
47	A rapid analytical method for the detection of plasma volume expanders and mannitol based on the urinary saccharides and polyalcohols profile. Drug Testing and Analysis, 2011, 3, 896-905.	1.6	5
48	Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control. Analytical and Bioanalytical Chemistry, 2011, 401, 529-541.	1.9	9
49	Urine stability and steroid profile: Towards a screening index of urine sample degradation for anti-doping purpose. Analytica Chimica Acta, 2011, 683, 221-226.	2.6	44
50	A simple and rapid preâ€confirmation method to distinguish endogenous human haemoglobin from synthetic haemoglobinâ€based oxygen carriers in doping control. Electrophoresis, 2011, 32, 2915-2918.	1.3	5
51	A rapid screening LCâ€MS/MS method based on conventional HPLC pumps for the analysis of low molecular weight xenobiotics: application to doping control analysis. Drug Testing and Analysis, 2010, 2, 311-322.	1.6	20
52	Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection. Analytica Chimica Acta, 2010, 657, 60-68.	2.6	18
53	Microwave irradiation for a fast gas chromatography–mass spectrometric analysis of polysaccharide-based plasma volume expanders in human urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3024-3032.	1.2	8
54	Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2010, 24, 749-760.	0.7	19

#	Article	IF	CITATIONS
55	Rapid screening of betaâ€adrenergic agents and related compounds in human urine for antiâ€doping purpose using capillary electrophoresis with dynamic coating. Journal of Separation Science, 2009, 32, 3562-3570.	1.3	21
56	A screening method for the detection of synthetic glucocorticosteroids in human urine by liquid chromatography–mass spectrometry based on class-characteristic fragmentation pathways. Analytical and Bioanalytical Chemistry, 2008, 390, 1389-1402.	1.9	61
57	A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Analytical and Bioanalytical Chemistry, 2008, 392, 681-698.	1.9	106
58	A Mass Spectrometric Approach for the Study of the Metabolism of Clomiphene, Tamoxifen and Toremifene by Liquid Chromatography Time-of-Flight Spectroscopy. European Journal of Mass Spectrometry, 2008, 14, 171-180.	0.5	40
59	A fast liquid chromatographic/mass spectrometric screening method for the simultaneous detection of synthetic glucocorticoids, some stimulants, anti-oestrogen drugs and synthetic anabolic steroids. Rapid Communications in Mass Spectrometry, 2006, 20, 3465-3476.	0.7	91
60	Effect of the systemic versus inhalatory administration of synthetic glucocorticoids on the urinary steroid profile as studied by gas chromatography–mass spectrometry. Analytica Chimica Acta, 2006, 559, 30-36.	2.6	18